Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

Cancer risk in psoriatic patients

A new study published in February 2020 in the journal JAMA Dermatology reports that there is a 21% increased risk of cancer in patients with psoriasis, but not with psoriatic arthritis alone.

19 Feb 2020

Research project moves one step closer to personalized treatment of rheumatic diseases

When a patient is diagnosed with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis, prescribing the correct type of medicine is a case of trial and error.

29 Jan 2020

Holistic Approaches to Psoriasis Treatment

Holistic approaches to psoriasis treatment involves lifestyle advice about weight, smoking, alcohol, sleep, exercise, and other factors.

From J&J Innovative Medicine 22 Jan 2020

Pathios appoints Stuart Hughes as CEO and announces US$8.8M Series A financing round

Pathios Therapeutics Limited, an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialization Fund managed by Brandon Capital.

9 Jan 2020

Age of psoriasis onset decides if the skin or joints act up first

People with psoriatic arthritis may initially present with either psoriasis or arthritis as the first symptom/sign of this illness. Now, a new study presented at the 2019 ACR/ARP Annual Meeting shows that the age at which psoriasis develops is a key predictor of which shows up first. Early-onset psoriasis is not strongly associated with arthritis while late-onset psoriasis is.

11 Nov 2019

Methotrexate reduces joint damage in hand osteoarthritis

A new study presented at the 2019 ACR/ARP meeting shows that methotrexate stopped further damage to the hand joints and even perhaps improved bone remodeling in patients with osteoarthritis (OA) of the hand, when they were assessed at 3 and 12 months.

11 Nov 2019

Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis

According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis.

11 Nov 2019

Psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis

In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found that the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

11 Nov 2019

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.

10 Nov 2019

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.

10 Nov 2019

Healthiest gut bacteria with plant-based or Mediterranean diet

A new study shows that specific foods that are supplied by either a plant-based or a Mediterranean-type diet can protect the gut against inflammatory disorders, by selectively promoting the growth of anti-inflammatory bacteria.

21 Oct 2019

Diagnostic value of ultrasound in comparing different types of arthritis

Ultrasound is a non-invasive and relatively inexpensive means of diagnosing a number of medical conditions. This review presents an analysis of the diagnostic value of ultrasound to draw comparison between different types of arthritic conditions.

12 Aug 2019

Finding potential treatments for autoimmune diseases

More than 50 million Americans are affected by an autoimmune disease, with women at an increased risk for developing one.

7 May 2019

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

Today, the American College of Rheumatology, in partnership with the Arthritis Foundation, released two guidelines on juvenile idiopathic arthritis.

30 Apr 2019

ACR and NPF release joint treatment guideline for psoriatic arthritis

The American College of Rheumatology and National Psoriasis Foundation have released a joint treatment guideline for psoriatic arthritis that provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for treatment-naïve patients with active PsA and patients who continue to have active PsA despite treatment.

4 Dec 2018

NPF grants support advancement of psoriatic disease research

The National Psoriasis Foundation, NPF, has awarded $2.3 million in research grants and fellowships in 2018. This year's awards bring the total amount NPF has invested in the advancement of psoriatic disease research to more than $19 million.

2 Nov 2018

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Survey: Psoriasis patients expect treatment to go beyond just clear skin and safety

Novartis, a leader in immuno-dermatology, announced today new data from a patient preference survey showing psoriasis patients want their treatment to go beyond just clear skin and safety.

12 Sep 2018

Psoriatic Arthritis News and Research

Further Reading

Cancer risk in psoriatic patients

Research project moves one step closer to personalized treatment of rheumatic diseases

Holistic Approaches to Psoriasis Treatment

Pathios appoints Stuart Hughes as CEO and announces US$8.8M Series A financing round

Age of psoriasis onset decides if the skin or joints act up first

Methotrexate reduces joint damage in hand osteoarthritis

Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis

Psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Healthiest gut bacteria with plant-based or Mediterranean diet

Diagnostic value of ultrasound in comparing different types of arthritis

Finding potential treatments for autoimmune diseases

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

ACR and NPF release joint treatment guideline for psoriatic arthritis

NPF grants support advancement of psoriatic disease research

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Survey: Psoriasis patients expect treatment to go beyond just clear skin and safety

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News